Loading
Sentiment · FY2026 Q2
On July 23, 2026, GE HealthCare said CFO James K. (Jay) Saccaro will resign effective August 14, 2026 to take a role outside the medical technology industry. Controller and Chief Accounting Officer George Newcomb, age 59, was named interim CFO effective the same date while the company searches for a permanent successor. Newcomb will continue to serve as Controller and Chief Accounting Officer.
| Analyst | Firm | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Larry Biegelsen | Wells Fargo | 14 (0%) |
| Vijay Kumar | Evercore ISI | 13 (15%) |
| Robbie Marcus | JPMorgan | 12 (17%) |
| David Roman | Goldman Sachs | 12 (8%) |
| Matt Taylor | Jefferies | 8 (0%) |
| Anthony Petrone | Mizuho Securities | 8 (0%) |
| Joanne Wuensch | Citigroup | 7 (0%) |
| Travis Steed | Bank of America | 6 (17%) |
| Craig Bijou | Bank of America | 4 (75%) |
| Rick Wise | Stifel | 4 (0%) |
| Firm | Analysts | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Wells Fargo | 1 | 14 (0%) |
| Evercore ISI | 1 | 13 (15%) |
| JPMorgan | 1 | 12 (17%) |
| Goldman Sachs | 1 |
| 12 (8%) |
| Bank of America | 2 | 10 (40%) |
| Jefferies | 1 | 8 (0%) |
| Mizuho Securities | 1 | 8 (0%) |
| Citigroup | 1 | 7 (0%) |
Revenue grew 2.9% organically with adjusted EPS of $0.99 as input cost inflation pressured profitability and prompted a reduction in FY2026 EPS guidance from $4.95-$5.15 to $4.80-$5.00. Photon Counting CT cleared regulatory hurdles in the U.S. and Japan, and Flyrcado dose ramp accelerated with a broadening customer base. A PDx supplier issue disrupted an otherwise strong quarter, and the PCS segment continued to decline with H2 recovery expected.
Revenue Growth | Margin | Product Launch | Demand | Competitive Dynamics | Innovation & R&D | Geographic Expansion | Trade Tariffs | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 4 | 4 | 3 | 3 | 3 | 2 | ||
| 2025Q1 | 1 | 1 | 2 | 3 | 2 | 3 | 8 | |
| 2025Q2 | 5 | 3 | 3 | 4 | 1 | 3 | 2 | 1 |
| 2025Q3 | 6 | 2 | 5 | 3 | 4 | 4 | 1 | 1 |
| 2025Q4 | 4 | 2 | 3 | 3 | 3 | 2 | 2 | |
| 2026Q1 | 2 | 6 | 2 | 1 | 4 | 4 | 1 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4 | 1 | 5 | 6 | 4 | 2 |
| Margin | 4 | 1 | 3 | 2 | 2 | 6 |
| Product Launch | 3 | 2 | 3 | 5 | 3 | 2 |
| Demand | 3 | 3 | 4 | 3 | 3 | 1 |
| Competitive Dynamics | 3 | 1 | 4 | 3 | 4 | |
| Innovation & R&D | 2 | 3 | 4 | 2 | 4 | |
| Geographic Expansion | 2 | 3 | 2 | 1 | 2 | 1 |
| Trade Tariffs | 8 | 1 | 1 | 1 |
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $5.32B | +2.2% | $1.57 | +78.4% | 42.8% | 15.1% | 13.5% | $811M |
| FY2025 Q1 | $4.78B | +2.7% | $1.23 | +51.9% | 42.1% | 13.2% | 11.8% | $98M |
| FY2025 Q2 | $5.01B | +3.5% | $1.06 | +14.0% | 39.7% | 13.1% | 9.7% | $8M |
| FY2025 Q3 | $5.14B | +5.8% | $0.98 | -3.9% | 38.7% | 12.7% | 8.7% | $483M |
| FY2025 Q4 | $4.67B | +6.7% | $0.38 | -75.8% | 54.3% | 14.2% | 3.9% | $917M |
| FY2026 Q1 | $5.13B | +7.4% | $0.85 | -30.9% | 38.5% | 10.0% | 7.6% | $112M |
| FY2026 Q2 | $5.29B | +5.8% | $1.24 | +17.0% | 41.2% | 14.0% | 10.8% | $-617M |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
What GEHC and other companies said about each other on FY2026 Q1 earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“we're getting better traction with our JV, which -- that we have a Sinopharm on DBPs in certain tenders.”
GE HealthCare reports improving traction from its China joint venture with Sinopharm on domestic-brand products in certain tenders.
“EBIT margin declined year-over-year primarily due to the discrete supplier issue, planned investments in our radiopharmaceutical pipeline and the Nihon Medi-Physics acquisition.”
GE HealthCare cites its Nihon Medi-Physics acquisition as one factor weighing on Pharmaceutical Diagnostics segment margins in the quarter.
“We also completed the acquisition of Intelerad in the first quarter. This advances our strategy to deliver a fully connected cloud-first enterprise imaging ecosystem that spans hospitals and outpatient settings.”
GE HealthCare closed its acquisition of Intelerad, an enterprise imaging/cloud software provider, to expand its AI, cloud and recurring-revenue capabilities.
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
GEHC GE HealthCare | 4 | +7.4% | |
| TEM Tempus AI, Inc. | 9 | +36.1% | |
| VEEV Veeva Systems Inc. | 9 | +16.0% |